Insider Selling: Vaxcyte (NASDAQ:PCVX) COO Sells 2,250 Shares

by · The Markets Daily

Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) COO Jim Wassil sold 2,250 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $53.86, for a total transaction of $121,185.00. Following the transaction, the chief operating officer directly owned 157,541 shares of the company’s stock, valued at $8,485,158.26. This represents a 1.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

  • On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.33, for a total transaction of $126,742.50.
  • On Monday, June 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $49.52, for a total value of $111,420.00.

Vaxcyte Stock Performance

Shares of Vaxcyte stock traded up $1.23 during midday trading on Wednesday, hitting $55.92. The company had a trading volume of 886,273 shares, compared to its average volume of 1,429,150. The stock has a market capitalization of $8.07 billion, a P/E ratio of -8.13 and a beta of 1.23. The company has a 50 day moving average of $53.47 and a 200 day moving average of $55.05. Vaxcyte, Inc. has a 52-week low of $29.08 and a 52-week high of $65.00.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.06) by $0.09. Equities research analysts forecast that Vaxcyte, Inc. will post -7.91 EPS for the current year.

Institutional Trading of Vaxcyte

Several institutional investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC increased its holdings in shares of Vaxcyte by 33.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after purchasing an additional 184 shares in the last quarter. Meeder Advisory Services Inc. lifted its holdings in shares of Vaxcyte by 2.9% during the first quarter. Meeder Advisory Services Inc. now owns 8,335 shares of the company’s stock valued at $484,000 after purchasing an additional 231 shares in the last quarter. CWM LLC lifted its holdings in shares of Vaxcyte by 9.0% during the fourth quarter. CWM LLC now owns 2,840 shares of the company’s stock valued at $131,000 after purchasing an additional 234 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Vaxcyte by 7.0% during the first quarter. Principal Financial Group Inc. now owns 5,275 shares of the company’s stock valued at $307,000 after buying an additional 343 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in shares of Vaxcyte by 156.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after buying an additional 364 shares during the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on PCVX shares. Wall Street Zen cut shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Zacks Research lowered shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $86.00.

Check Out Our Latest Research Report on Vaxcyte

Vaxcyte Company Profile

(Get Free Report)

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.

Further Reading